MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition

MANNKIND CORP

2025-Q3 EPS reported $0.07 revenue$237,011,000

Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).
GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.
Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.
Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.
Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.